c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity.The mature receptor is made up of the alpha and beta subunits, which are disulfide linked after post-translational cleavage of the primary single chain precursor protein. A membrane receptor called c-Met is crucial for both wound healing and embryonic development. The c-Met receptor's sole known ligand is hepatocyte growth factor (HGF). Cells of epithelial origin typically express c-Met, whereas cells of mesenchymal origin only express HGF. In response to HGF stimulation, c-Met triggers a number of biological processes that together give rise to the invasive growth program.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69310 | Adrixetinib | 2394874-66-7 | Adrixetinib is a PTK (protein tyrosine kinase) inhibitor (antagonist) with anti-tumor effects. |
|
V3459 | AMG 337 | 1173699-31-4 | AMG-337 is a novel, potent and highly selective small molecule ATP-competitive MET kinase inhibitor. |
|
V0599 | AMG-208 | 1002304-34-8 | AMG 208 (AMG-208) is a novel, highly potent and selective triazolopyridazine-based small molecule inhibitor of c-Met with potential antineoplastic activity. |
|
V0600 | AMG-458 | 913376-83-7 | AMG 458 (AMG-458) is a novel c-Met inhibitor with potential anticancer activity. |
|
V78072 | Antitumor agent-111 | Antitumor agent-111 (compound 46) is a c-Met kinase inhibitor (IC50=46 nM) with anti-tumor and antiproliferation activities. | |
|
V40400 | BAY-474 | 1033767-86-0 | BAY-474 is a tyrosine protein kinase c-MET inhibitor. |
|
V7744 | BMS-2 | 888719-03-7 | MET kinase-IN-4 is an orally bioactive Met kinase inhibitor. |
|
V0602 | BMS-754807 | 1001350-96-4 | BMS-754807 (BMS754807) is an orally bioavailable small molecule inhibitor of IGF-1R/InsR (growth factor 1 receptor/insulin receptor family kinases) with potential antineoplastic activity. |
|
V0594 | BMS-777607 (BMS-817378; ASLAN-002) | 1025720-94-8 | BMS-777607 (also called as BMS817378; ASLAN002) is anorally bioavailableinhibitor of the tyrosine kinase c-Metwith potential antitumor activity. |
|
V69311 | Boditrectinib (HL5101) | 1940165-80-9 | Boditrectinib is a potent tyrosine kinase inhibitor. |
|
V69317 | Boditrectinib oxalate (HL5101 oxalate) | 2773577-41-4 | Boditrectinib oxalate is a potent tyrosine kinase inhibitor. |
|
V32843 | Bozitinib (Vebreltinib) | 1440964-89-5 | Bozitinib (Vebreltinib;formerlyAPL-101/PLB-1001, CBT-101)is a novel, an ATP-competitive,and highly selective c-MET kinase inhibitor with blood-brain barrier permeability. |
|
V69315 | c-Met-IN-15 | 330572-32-2 | c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. |
|
V69321 | c-Met-IN-16 | 1208248-23-0 | c-Met-IN-16 is a c-Met inhibitor that may be utilized in cancer-related research. |
|
V79828 | c-Met-IN-17 | c-Met-IN-17 is a highly effective c-Met kinase inhibitor (antagonist) with IC50 of 0.031μM. | |
|
V79831 | c-Met-IN-18 | c-Met-IN-18 is an ATP-competitive type III c-MET inhibitor of WT and D1228V mutant c-MET. | |
|
V78835 | c-Met-IN-19 | c-Met-IN-19 (Compound 21j) is a c-Met inhibitor (IC50= 1.99 nM). | |
|
V69318 | Canlitinib | 2222730-78-9 | Canlitinib is a tyrosine kinase inhibitor (TKI), patent number WO2018072614 (IV-2). |
|
V0598 | Capmatinib (INCB28060; INC-280) | 1029712-80-8 | Capmatinib (formerly also known as INCB-28060; INC280; Tabrecta) is a novel, potent, orally bioavailable, ATP-competitive inhibitor of c-METwith potential antitumor activity. |
|
V2685 | Capmatinib 2HCl | 1197376-85-4 | Capmatinib 2HCl (INCB28060; INC-280; Tabrecta), the dihydrochloride salt ofCapmatinib, is an orally bioavailable and ATP-competitive inhibitor of c-MET approved by FDA on August 10, 2022 by the US FDA for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
